Profile for Austria Patent: E554754

US Patent Family Members and Approved Drugs for Austria Patent: E554754

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
7,816,404	Apr 17, 2029	Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate
7,816,404	Apr 17, 2029	Rockwell Medical Inc	TRIFERIC AVNU	ferric pyrophosphate citrate

Key insights for pharmaceutical patentability - Austria patent ATE554754

Last updated: April 26, 2026

What is covered by the Austrian patent for ATE554754, and how does it sit in the patent landscape?

No analysis is possible from the information provided. The identifier ATE554754 is not sufficient to uniquely determine the exact Austrian patent publication/application, its full claim set, priority/filing data, or its family members. Without the underlying patent document (publication number or claims text), any “scope and claims” breakdown would be non-verifiable and could misstate coverage.

What is the Austrian patent for ATE554754 that must be analyzed?

There is no way to map ATE554754 to:

• an Austrian publication number (e.g., AT publication format),
• an application number,
• a grant number, or
• the official claim set in force.

What claims define the legal scope in Austria?

Claim scope analysis requires the exact claim language, including:

• independent claim categories (composition, method, use, device, kit, process),
• claim dependencies (where dependent claims narrow the independent claims),
• claim limitations tied to:
  • molecule identity (structure/sequence/Markush definition),
  • salt/hydrate/crystal form,
  • dose regimens,
  • route of administration,
  • patient population,
  • biomarker or mechanism,
  • manufacturing or purity specs,
  • polymorph and particle size (if present).

No claims text is available, so scope cannot be analyzed.

How does the patent landscape look across the family (AT, EP, WO, US)?

A credible landscape needs:

• the priority chain,
• WO/EP/US equivalents,
• claim-by-claim overlaps across jurisdictions,
• prosecution status indicators (grants, objections, withdrawals, narrowing amendments),
• later patent families and “evergreening” links (formulations, crystal forms, new dosing, new indications).

None of this can be derived from ATE554754 alone.

What can be concluded about freedom-to-operate (FTO) in Austria?

FTO depends on:

• claim breadth in Austria as actually granted,
• status (pending vs granted),
• term/validity constraints and potential limitations,
• whether a later filing date changes exclusivity and enforcement risk.

Those facts cannot be established without the actual Austrian patent record and claims.

---

Key Takeaways

• A complete, accurate scope and claims analysis cannot be produced from ATE554754 as provided.
• Patent landscape mapping (family, claim overlap, and FTO relevance) also cannot be produced without the exact Austrian publication/application and claim text.
• Any attempt would risk misstating the legal scope.

---

FAQs

1. Can “ATE554754” be used to identify the Austrian patent publication?
   Not reliably. The identifier is not a standard, verifiable Austrian patent publication identifier without a corresponding publication/application number.

2. Why can’t scope be inferred without the claims text?
   Patent scope in Austria depends on the precise claim language and dependencies in the official publication or grant.

3. What does a proper Austrian drug patent scope analysis require?
   The exact Austrian publication/grant and its full claim set, plus priority and family data to map equivalents.

4. How is the patent landscape typically constructed for a drug patent?
   By tracing priority families (WO/EP/AT/US), then comparing claim elements across jurisdictions and time.

5. What determines whether this matters for FTO in Austria?
   The granted (or pending) claim breadth, validity status, and enforcement posture, all of which require the official patent record and claims.

---

References

No sources could be cited because no specific patent document tied to “ATE554754” was provided or verifiable from the input.